Ospemifene for vulvar and vaginal atrophy: an overview
The menopause-related decline in estrogen levels leads to an array of genital, sexual, and urinary symptoms collectively known as genitourinary syndrome of menopause. The constellation of symptoms associated with vulvar and vaginal atrophy (VVA) can have a profoundly detrimental effect on a woman...
Saved in:
Main Author: | Santiago Palacios (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2020-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
by: Zuramis Estrada Blanco, et al.
Published: (2020) -
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
by: Palacios S, et al.
Published: (2016) -
Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles
by: María del Carmen Pingarrón Santofimia, et al.
Published: (2020) -
Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
by: Mariella Lilue, et al.
Published: (2020) -
Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
by: Ana Rosa Jurado López, et al.
Published: (2020)